In patients with active RA inadequately responsive to a TNF antagonist, abatacept in combination with background DMARD therapy was more effective than background DMARD therapy alone in reducing the signs and symptoms of RA and improving physical function (Fig. 2). This evidence concerns the gene TNF and rheumatoid arthritis.